Retatrutide, Kodiak, and six FDA decisions

Retatrutide posted the strongest Phase 3 weight-loss number ever recorded in diabetes. Plus: a dead eye drug beat Eylea twice, Roche killed its muscle bet, and the FDA's busiest week of the year.

The one-time cure era is having a week

This week: the FDA approved the first gene therapy for a fatal childhood brain disease, a one-time eye gene therapy posted the first pivotal win ever in XLRP, and three frontier tech companies pushed into drug discovery in seven days.

Enhertu, a virtual cell, and a confirmatory failure

The AI drug that might slow aging

Plus: Wegovy goes pediatric, Novartis's worst week, and the IPO window reopens.